



Rev. 04/01

PATENTS
Docket No. NaPro-18

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Kmiec et al.
Application No.: 10/681,074 Confirmation No.: 7677
Filed : October 7, 2003
For : METHODS AND COMPOSITIONS FOR REDUCING
SCREENING IN OLIGONUCLEOTIDE-DIRECTED
NUCLEIC ACID SEQUENCE ALTERATION
Group Art Unit : 1645

Hon. Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL LETTER FOR
INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith is an Information Disclosure Statement in the above-identified application. This Statement is submitted:


- ☐ [] within three months of the application filing date;
- ☒ [X] more than three months from the application filing date but before the mailing date of the first Office Action on the merits.

In accordance with 37 C.F.R. § 1.97, submission of this Statement requires no fee. However, if for any reason a fee is due, the Director is hereby authorized to charge payment of any fees required in connection with this

Information Disclosure Statement to Deposit Account
No. 06-1075. A duplicate copy of this letter is
transmitted herewith.

Respectfully submitted,

19 FEB 2004



Daniel M. Becker
Registration No. 38,376
Attorney for Applicants

FISH & NEAVE
Customer No. 1473
1251 Avenue of the Americas
New York, New York 10020-1104
Tel.: (650) 617-4000


I hereby Certify that this
Correspondence is being
Deposited with the U.S.
Postal Service as First
Class Mail in an Envelope
Addressed to : HON.
COMMISSIONER FOR PATENTS,
P.O. BOX 1450, Alexandria,
VA 22313-1450 on:

2-19-04
Date of Deposit

Lorraine Coke
Name of Person Signing


Signature of Person Signing

2-19-04
Date of Signature



PATENTS

Docket No. NaPro-18

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Kmiec et al.
Application No.: 10/681,074 Confirmation No.:7677
Filed : October 7, 2003
For : METHODS AND COMPOSITIONS FOR REDUCING
SCREENING IN OLIGONUCLEOTIDE-DIRECTED
NUCLEIC ACID SEQUENCE ALTERATION
Group Art Unit : 1645

Hon. Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98,
applicants hereby make the following documents of record in
the above identified application:*

U.S. Patents and Patent Publications

6,573,046	06/03/03	Kmiec et al.
6,479,292	11/12/02	Metz et al.
6,303,376	10/16/01	Glazer
6,271,360	08/07/01	Metz
6,268,490	07/31/01	Imanishi et al.
6,136,601	10/24/00	Meyer
6,043,060	03/28/00	Imanishi
6,004,804	12/21/99	Kumar

* Applicants reserve the right to challenge the status
of any of the cited documents as prior art.

5,962,426	10/05/99	Glazer
5,955,363	09/21/99	Lewis
5,912,340	06/15/99	Kutyavin
5,888,983	03/30/99	Kmiec et al.
5,871,984	02/16/99	Kmiec
5,801,154	09/01/98	Baracchini
5,795,972	08/18/98	Kmiec
5,780,296	07/14/98	Holloman et al.
5,776,744	07/07/98	Glazer et al.
5,760,012	06/02/98	Kmiec et al.
5,756,325	05/26/98	Kmiec
5,731,181	03/24/98	Kmiec
5,565,350	10/15/96	Kmiec
5,422,251	06/06/95	Fresco
US 2003/0217377	11/20/03	Kmiec et al.
US 2003/0051270	03/13/03	Kmiec et al.
US 2002/0143952	10/03/02	Sugiarto et al.
US 2002/0119570	08/29/02	Yoon

Foreign Patents

WO 03/075856	09/18/03	PCT
WO 03/027640	04/03/03	PCT
WO 03/027265	04/03/03	PCT
WO 03/027264	04/03/03	PCT
WO 02/26967	04/04/02	PCT
WO 02/10364	02/07/02	PCT
WO 01/92512	12/06/01	PCT
WO 01/87914	11/22/01	PCT
WO 01/73002	10/04/01	PCT
WO 01/24615	04/12/01	PCT
WO 01/15740	03/08/01	PCT
WO 00/66604	11/09/00	PCT
WO 00/56748	09/28/00	PCT
WO 00/51424	09/08/00	PCT
WO 00/23567	04/27/00	PCT
WO 99/58702	11/18/99	PCT

WO 99/14226	03/25/99	PCT
WO 98/39352	09/11/98	PCT

Other Documents

Alexeev et al., "Stable and inheritable changes in genotype and phenotype of albino melanocytes induced by an RNA-DNA oligonucleotide," *Nature Biotech.* 16:1343-1346 (1998)

Campbell et al., "Homologous recombination involving small single-stranded oligonucleotides in human cells," *New Biologist* 1:223-227 (1989)

Chan et al., "Targeted correction of an episomal gene in mammalian cells by a short DNA fragment tethered to a triplex-forming oligonucleotide," *J. Biol. Chem.* 274:11541-11548 (1999)

Chan et al., "Triplex DNA: fundamentals, advances, and potential applications for gene therapy," *J. Mol. Med.* 75:267-282 (1997)

Chang et al., "Transgenic knockout mice exclusively expressing human hemoglobin S after transfer of a 240-kb β -globin yeast artificial chromosome: A mouse model of sickle cell anemia", *Proc. Natl. Acad. Sci. USA* 95:14886-14890 (1998)

Chumakov et al., "A YAC contig map of the human genome", *Nature* 377:175-297 (1995)

Cohen et al., "A first-generation physical map of the human genome", *Nature* 336: 698-701 (1995)

Cole-Strauss et al., "Correction of the mutation responsible for sickle cell anemia by an RNA-DNA oligonucleotide," *Science* 273:1386-1389 (1996)

Couch et al., "Mutations and Polymorphisms in the Familial Early-Onset Breast Cancer (BRCA1) Gene", *Hum. Mutat.* 8:8-18 (1996)

Crystal, Ronald G., "Transfer of Genes to Humans: Early Lessons and Obstacles to Success," *Science* 270: 404-410 (1995)

Culver et al., "Correction of chromosomal point mutations in human cells with bifunctional oligonucleotides," *Nat. Biotechnol.* 17:989-993 (1999)

Ford et al., "Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families", *Am. J. Hum. Genet.* 62: 676-689 (1998)

Gamper et al., "A plausible mechanism for gene correction by chimeric oligonucleotides," *Biochemistry* 39(19): 5808-16 (2000)

Gamper et al., "The DNA strand of chimeric RNA/DNA oligonucleotides can direct gene repair/conversion activity in mammalian and plant cell-free extracts," *Nucleic Acids Res.* 28:4332-4339 (2000)

Gnirke et al., "Microinjection of Intact 200- to 500kb Fragments of YAC DNA into Mammalian Cells", *Genomics* 15:659-667 (1993)

Igoucheva et al., "Targeted gene correction by small single-stranded oligonucleotides in mammalian cells," *Gene Therapy* 8:391-399 (2001)

Kaji et al., "Gene and Stem Cell Therapies," *JAMA* 285(5): 545-550 (2001)

Kmiec et al., "Targeted gene repair in mammalian cells using chimeric RNA/DNA oligonucleotides," *Cold Spring Harbor Monograph Series* 36: 643-670 (1999)

Knijff et al., "Genetic Heterogeneity of Apolipoprotein E and Its Influence on Plasma Lipid and Lipoprotein Levels", *Hum. Mutat.* 4:178-194 (1994)

Kren et al., "Correction of the UDP-glucuronosyltransferase gene defect in the Gunn rat model of Crigler-Najjar syndrome type I with a chimeric oligonucleotide," *Proc. Natl. Acad. Sci. USA* 96:10349-10354 (1999)

Kunzelmann et al., "Gene targeting of CFTR DNA in CF epithelial cells," *Gene Ther.* 3:859-867 (1996)

Liu et al., "In vivo gene repair of point and frameshift mutations directed by chimeric RNA/DNA oligonucleotides and modified single-stranded oligonucleotides," *Nucl. Acids Res.* 29(20): 4238-50 (2001)

Liu et al., "Strand Bias in Targeted Gene Repair Is Influenced by Transcriptional Repair", *Mol. Cell Biol.* 22:3852-3863 (2002)

Liu et al., "Rad51p and Rad54p, but not Rad52p, elevate gene repair in *Saccharomyces cerevisiae* directed by modified single-stranded oligonucleotide vectors", *Nucleic Acids Res.* 30:13 2742-50 (2002)

Marks et al., "Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells", *J. Natl. Canc. Inst.* 92(15):1210-1216

Moerschell et al., "Transformation of yeast with synthetic oligonucleotides," *Proc. Natl. Acad. Sci. USA* 85:524-528 (1988)

Orum et al., "Detection of the factor V Leiden mutation by direct allele-specific hybridization of PCR amplicons to photoimmobilized locked nucleic acids," *Clinical Chemistry* 45(11): 1898-1905 (1999)

Parekh-Olmedo et al., "Targeted Neucleotide Exchange in *Saccharomyces cerevisiae* Directed by Short Oligonucleotides Containing Locked Nucleic Acids", *Chem. Biol.* 9:1073-1084 (2002)

Rando et al., "Rescue of dystrophin expression in *mdx* mouse muscle by RNA/DNA oligonucleotides," *Proc. Natl. Acad. Sci. USA* 97:5363-5368 (2000)

Rice et al., "The potential of nucleic acid repair in functional genomics," *Nature Biotech.* 19(4): 321-26 (2001)

Santisteban et al., "Three new adenosine deaminase mutations that define a splicing enhancer and cause severe and partial phenotypes: Implications for evolution of a CpG hotspot and expression of a transduced ADA cDNA," *Human Molec. Genetics* 4(11): 2081-87 (1995)

Sayers et al., "5'-3' Exonucleases in Phosphorothioate-based Oligonucleotide-directed Mutagenesis," *Nucleic Acids Research* 16(3): 791-801 (1988)

Spain et al., "Truncated BRCA2 is cytoplasmic: Implications for cancer-linked mutations", *Proc. Natl. Acad. Sci. USA* 96:13920-13925 (1999)

Tizzano et al., "Cystic fibrosis: Beyond the gene to therapy", *J. Pediat.* 120: 337-349 (1992)

Vasquez et al., "Chromosomal mutations induced by triplex-forming oligonucleotides in mammalian cells," *Nucl. Acids Res.* 27:1176-1181 (1999)

Vasquez et al., "Specific mutations induced by triplex-forming oligonucleotides in mice," *Science* 290:530-532 (2000)

Verma et al., "Gene Therapy- Promises, Problems, and Prospects," *Nature* 389: 239-242 (1997)

Welsh et al., "Cystic Fibrosis: Transmembrane Conductance Regulator: A Chloride Channel with Novel Regulation", *Neuron*, 8:821-829 (1992)

Woolf et al., "Toward the therapeutic editing of mutated RNA sequences," *Proc. Natl. Acad. Sci. USA* 92: 8298-8302 (1995)

Xu et al., "Activation of human γ -globin gene expression via triplex-forming oligonucleotide (TFO)-directed mutations in the γ -globin gene 5' flanking region," *Gene* 242:219-228 (2000)

Yamamoto et al., "Parameters Affecting the Frequencies of Transformation and Co-transformation with Synthetic Oligonucleotides in Yeast", *Yeast* 8:935(1992)

Yamamoto et al., "Strand-specificity in the transformation of yeast with synthetic oligonucleotides," *Genetics* 131:811-819 (1992)

Yanez et al., "Therapeutic gene targeting," *Gene Therapy* 5:149-159 (1998)


Yu et al., "An efficient recombination system for chromosome engineering in *Escherichia coli*", *Proc. Natl. Acad. Sci USA* 97:5978-5983 (2000)

Pursuant to the PTO's waiver of the requirement under 37 CFR 1.98 (a)(2)(i), 1276 OG 55, applicants have not submitted copies of each cited U.S. patent and each U.S. patent application publication. Copies of the aforementioned foreign patent publications and other documents, which are listed on the accompanying Form PTO-1449, are enclosed herewith.

It is respectfully requested that these documents be (1) fully considered by the Patent and Trademark Office during the examination of this application; and (2) printed on any patent that may issue on this application. Applicants request that a copy of Form PTO-1449, as considered and initialed by the Examiner, be returned with the next communication.

An early and favorable action is respectfully requested.

Respectfully submitted,


Daniel M. Becker
Registration No. 38, 376
Attorney for Applicants

FISH & NEAVE
Customer No. 1473
1251 Avenue of the Americas
New York, New York 10020-1104
Tel.: (650) 617-4000

19 FEB 2004
I hereby Certify that this
Correspondence is being
Deposited with the U.S.
Postal Service as First
Class Mail in an Envelope
Addressed to : EON.
COMMISSIONER FOR PATENTS,
P.O. BOX 1450, Alexandria,
VA 22313-1450 on:

2-19-04
Date of Deposit
Lorraine Cole
Name of Person Signing
Lorraine Cole
Signature of Person Signing
2-19-04
Date of Signature



PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE
STATEMENT BY APPLICANTATTY. DOCKET NO.
NaPro-18SERIAL NO.
10/681,074APPLICANT
Eric B. Kmiec et al.FILING DATE
October 7, 2003GROUP
1645

47U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,573,046	06/03/03	Kmiec et al.			
	6,479,292	11/12/02	Metz et al.			
	6,303,376	10/16/01	Glazer			
	6,271,360	08/07/01	Metz			
	6,268,490	07/31/01	Imanishi et al.			
	6,136,601	10/24/00	Meyer			
	6,043,060	03/28/00	Imanishi			
	6,004,804	12/21/99	Kumar			
	5,962,426	10/05/99	Glazer			
	5,955,363	09/21/99	Lewis			
	5,912,340	06/15/99	Kutyavin			
	5,888,983	03/30/99	Kmiec et al.			
	5,871,984	02/16/99	Kmiec			
	5,801,154	09/01/98	Baracchini			
	5,795,972	08/18/98	Kmiec			
	5,780,296	07/14/98	Holloman et al.			
	5,776,744	07/07/98	Glazer et al.			
	5,760,012	06/02/98	Kmiec et al.			
	5,756,325	05/26/98	Kmiec			
	5,731,181	03/24/98	Kmiec			
	5,565,350	10/15/96	Kmiec			
	5,422,251	06/06/95	Fresco			
	US 2003/0217377	11/20/03	Kmiec et al.			
	US 2003/0051270	03/13/03	Kmiec et al.			
	US 2002/0143952	10/03/02	Sugiarto et al.			
	US 2002/0119570	08/29/02	Yoon			

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. NaPro-18	SERIAL NO. 10/681,074
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Eric B. Kmiec et al.	
		FILING DATE October 7, 2003	GROUP 1645

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 03/075856	09/18/03	PCT				
	WO 03/027640	04/03/03	PCT				
	WO 03/027265	04/03/03	PCT				
	WO 03/027264	04/03/03	PCT				
	WO 02/26967	04/04/02	PCT				
	WO 02/10364	02/07/02	PCT				
	WO 01/92512	12/06/01	PCT				
	WO 01/87914	11/22/01	PCT				
	WO 01/73002	10/04/01	PCT				
	WO 01/24615	04/12/01	PCT				
	WO 01/15740	03/08/01	PCT				
	WO 00/66604	11/09/00	PCT				
	WO 00/56748	09/28/00	PCT				
	WO 00/51424	09/08/00	PCT				
	WO 00/23567	04/27/00	PCT				
	WO 99/58702	11/18/99	PCT				
	WO 99/14226	03/25/99	PCT				
	WO 98/39352	09/11/98	PCT				X

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Alexeev et al., "Stable and inheritable changes in genotype and phenotype of albino melanocytes induced by an RNA-DNA oligonucleotide," <i>Nature Biotech.</i> 16:1343-1346 (1998)
	Campbell et al., "Homologous recombination involving small single-stranded oligonucleotides in human cells," <i>New Biologist</i> 1:223-227 (1989)
	Chan et al., "Targeted correction of an episomal gene in mammalian cells by a short DNA fragment tethered to a triplex-forming oligonucleotide," <i>J. Biol. Chem.</i> 274:11541-11548 (1999)
	Chan et al., "Triplex DNA: fundamentals, advances, and potential applications for gene therapy," <i>J. Mol. Med.</i> 75:267-282 (1997)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. NaPro-18	SERIAL NO. 10/681,074
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Eric B. Kmiec et al.	
		FILING DATE October 7, 2003	GROUP 1645

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Chang et al., "Transgenic knockout mice exclusively expressing human hemoglobin S after transfer of a 240-kb β -globin yeast artificial chromosome: A mouse model of sickle cell anemia", <i>Proc. Natl. Acad. Sci. USA</i> 95:14886-14890 (1998)
	Chumakov et al., "A YAC contig map of the human genome", <i>Nature</i> 377:175-297 (1995)
	Cohen et al., "A first-generation physical map of the human genome", <i>Nature</i> 336: 698-701 (1995)
	Cole-Strauss et al., "Correction of the mutation responsible for sickle cell anemia by an RNA-DNA oligonucleotide," <i>Science</i> 273:1386-1389 (1996)
	Couch et al., "Mutations and Polymorphisms in the Familial Early-Onset Breast Cancer (BRCA1) Gene", <i>Hum. Mutat.</i> 8:8-18 (1996)
	Crystal, Ronald G., "Transfer of Genes to Humans: Early Lessons and Obstacles to Success," <i>Science</i> 270: 404-410 (1995)
	Culver et al., "Correction of chromosomal point mutations in human cells with bifunctional oligonucleotides," <i>Nat. Biotechnol.</i> 17:989-993 (1999)
	Ford et al., "Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families", <i>Am. J. Hum. Genet.</i> 62: 676-689 (1998)
	Gamper et al., "A plausible mechanism for gene correction by chimeric oligonucleotides," <i>Biochemistry</i> 39(19): 5808-16 (2000)
	Gamper et al., "The DNA strand of chimeric RNA/DNA oligonucleotides can direct gene repair/conversion activity in mammalian and plant cell-free extracts," <i>Nucleic Acids Res.</i> 28:4332-4339 (2000)
	Gnirke et al., "Microinjection of Intact 200- to 500kb Fragments of YAC DNA into Mammalian Cells", <i>Genomics</i> 15:659-667 (1993)
	Igoucheva et al., "Targeted gene correction by small single-stranded oligonucleotides in mammalian cells," <i>Gene Therapy</i> 8:391-399 (2001)
	Kaji et al., "Gene and Stem Cell Therapies," <i>JAMA</i> 285(5): 545-550 (2001)
	Kmiec et al., "Targeted gene repair in mammalian cells using chimeric RNA/DNA oligonucleotides," <i>Cold Spring Harbor Monograph Series</i> 36: 643-670 (1999)
	Knijff et al., "Genetic Heterogeneity of Apolipoprotein E and Its Influence on Plasma Lipid and Lipoprotein Levels", <i>Hum. Mutat.</i> 4:178-194 (1994)
	Kren et al., "Correction of the UDP-glucuronosyltransferase gene defect in the Gunn rat model of Crigler-Najjar syndrome type I with a chimeric oligonucleotide," <i>Proc. Natl. Acad. Sci. USA</i> 96:10349-10354 (1999)
	Kunzelmann et al., "Gene targeting of CFTR DNA in CF epithelial cells," <i>Gene Ther.</i> 3:859-867 (1996)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO.	SERIAL NO.
		NaPro-18	10/681,074
		APPLICANT Eric B. Kmiec et al.	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE October 7, 2003	GROUP 1645

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Liu et al., "In vivo gene repair of point and frameshift mutations directed by chimeric RNA/DNA oligonucleotides and modified single-stranded oligonucleotides," <i>Nucl. Acids Res.</i> 29(20): 4238-50 (2001)
	Liu et al., "Strand Bias in Targeted Gene Repair Is Influenced by Transcriptional Repair", <i>Mol. Cell Biol.</i> 22:3852-3863 (2002)
	Liu et al., "Rad51p and Rad54p, but not Rad52p, elevate gene repair in <i>Saccharomyces cerevisiae</i> directed by modified single-stranded oligonucleotide vectors", <i>Nucleic Acids Res.</i> 30:13 2742-50 (2002)
	Marks et al., "Histone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells", <i>J. Natl. Canc. Inst.</i> 92(15):1210-1216
	Moerschell et al., "Transformation of yeast with synthetic oligonucleotides," <i>Proc. Natl. Acad. Sci. USA</i> 85:524-528 (1988)
	Ørum et al., "Detection of the factor V Leiden mutation by direct allele-specific hybridization of PCR amplicons to photoimmobilized locked nucleic acids," <i>Clinical Chemistry</i> 45(11): 1898-1905 (1999)
	Parekh-Olmedo et al., "Targeted Nucleotide Exchange in <i>Saccharomyces cerevisiae</i> Directed by Short Oligonucleotides Containing Locked Nucleic Acids", <i>Chem. Biol.</i> 9:1073-1084 (2002)
	Rando et al., "Rescue of dystrophin expression in <i>mdx</i> mouse muscle by RNA/DNA oligonucleotides," <i>Proc. Natl. Acad. Sci. USA</i> 97:5363-5368 (2000)
	Rice et al., "The potential of nucleic acid repair in functional genomics," <i>Nature Biotech.</i> 19(4): 321-26 (2001)
	Santisteban et al., "Three new adenosine deaminase mutations that define a splicing enhancer and cause severe and partial phenotypes: Implications for evolution of a CpG hotspot and expression of a transduced ADA cDNA," <i>Human Molec. Genetics</i> 4(11): 2081-87 (1995)
	Sayers et al., "5'-3' Exonucleases in Phosphorothioate-based Oligonucleotide-directed Mutagenesis," <i>Nucleic Acids Research</i> 16(3): 791-801 (1988)
	Spain et al., "Truncated BRCA2 is cytoplasmic: Implications for cancer-linked mutations", <i>Proc. Natl. Acad. Sci. USA</i> 96:13920-13925 (1999)
	Tizzano et al., "Cystic fibrosis: Beyond the gene to therapy", <i>J. Pediat.</i> 120: 337-349 (1992)
	Vasquez et al., "Chromosomal mutations induced by triplex-forming oligonucleotides in mammalian cells," <i>Nucl. Acids Res.</i> 27:1176-1181 (1999)
	Vasquez et al., "Specific mutations induced by triplex-forming oligonucleotides in mice," <i>Science</i> 290:530-532 (2000)
	Verma et al., "Gene Therapy- Promises, Problems, and Prospects," <i>Nature</i> 389: 239-242 (1997)
	Welsh et al., "Cystic Fibrosis: Transmembrane Conductance Regulator: A Chloride Channel with Novel Regulation", <i>Neuron</i> , 8:821-829 (1992)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. NaPro-18	SERIAL NO. 10/681,074
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		APPLICANT Eric B. Kmiec et al.	
		FILING DATE October 7, 2003	GROUP 1645

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Woolf et al., "Toward the therapeutic editing of mutated RNA sequences," <i>Proc. Natl. Acad. Sci. USA</i> 92: 8298-8302 (1995)
	Xu et al., "Activation of human γ -globin gene expression via triplex-forming oligonucleotide (TFO)-directed mutations in the γ -globin gene 5' flanking region," <i>Gene</i> 242:219-228 (2000)
	Yamamoto et al., "Parameters Affecting the Frequencies of Transformation and Co-transformation with Synthetic Oligonucleotides in Yeast", <i>Yeast</i> 8:935(1992)
	Yamamoto et al., "Strand-specificity in the transformation of yeast with synthetic oligonucleotides," <i>Genetics</i> 131:811-819 (1992)
	Yanez et al., "Therapeutic gene targeting," <i>Gene Therapy</i> 5:149-159 (1998)
	Yu et al., "An efficient recombination system for chromosome engineering in <i>Escherichia coli</i> ", <i>Proc. Natl. Acad. Sci USA</i> 97:5978-5983 (2000)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.